目的 觀(guān)察舒利迭(50/500)對(duì)激素抵抗型哮喘患者的療效。方法 將36例激素抵抗型支氣管哮喘患者隨機(jī)分為舒利迭治療組和潑尼松治療組；另選18名激素敏感型哮喘患者為對(duì)照組。潑尼松治療組口服潑尼松治療，舒利迭治療組及對(duì)照組均給予舒利迭(50/500)治療，各組氨茶堿治療相同。記錄治療前、后患者的肺功能，并檢測(cè)血清IFN-γ和IL-4的量。結(jié)果 舒利迭治療組的總有效率高于潑尼松治療組，療效差異顯著（P＜0.05)，且兩組療效均低于對(duì)照組，差異顯著(P＜0.50)；舒利迭治療組的IFN-γ高于潑尼松治療組，但差異不顯著(P＞0.05)；舒利迭治療組的IL-4低于潑尼松治療組，且差異顯著(P＜0.05)。結(jié)論 應(yīng)用舒利迭(50/500)治療激素抵抗型哮喘，能一定程度改善肺功能，使用安全，值得在臨床推廣；且激素抵抗型哮喘的發(fā)病機(jī)制可能與IL-4升高有關(guān)。

Objective To investigate in effects of treatment using seretide on patients with glucocoticoid resistant asthma. Methods 36 Patients with glucocoticoid resistant asthma were randomly divided into seretide (50/500) treatment and prednisone treatment groups. And 18 patients with glucocoticoid sensitive asthma were control groups. The control group was given conventional treatment, the seretide (50/500) treatment group was given seretide (50/500) on the basis of conventional treatment. The parameters of lung function test and IFN-γ and IL-4 were measured before and after treatment. Results The efficient of the seretide (50/500) treatment group significantly higher than that of the prednisone treatment group. Efficacy difference between the two groups was significant (P＜0.05)；And two groups significantly lower than that control group, efficacy difference was significant (P＜0.05)；IFN-γ of the seretide (50/500) treatment group was higher than that of the prednisone treatment group. But efficacy difference between the two groups was not significant (P＞0.05)；IL-4 of the seretide (50/500) treatment group was significantly higher than that of the prednisone treatment group. Efficacy difference between the two groups was significant (P＜0.05)；Seretide had no obvious side effects. Conclusion Application of seretide (50/500) in the treatment of glucocoticoid resistant asthma can significantly improve blood gas indicators. The use is safe. It is worth promoting in the clinic. And the mechanism of glucocoticoid resistant asthma maybe relat to IL-4.